Outcomes of Helicobacter Pylori eradication on lipid profiles and cardiovascular disease risk: a systematic review, meta-analysis, and meta-regression Cardio-lipid outcomes of H.Pylori eradication
Gastroenterology and Hepatology from Bed to Bench,
,
2 Esfand 2026
,
Page 1-14 (e1)
https://doi.org/10.22037/ghfbb.v19i01.3232
Abstract
Aim: To evaluate the impacts of successful Helicobacter pylori (H. pylori) eradication on lipid profiles and cardiovascular disease (CVD) risk.
Background: Recent evidence suggests that H. pylori infection increases the risk of lipid impairment and CVD. However, the extent to which H. pylori eradication can reduce these risks remains inconclusive.
Methods: Searches were conducted across databases (PubMed, Scopus, and ScienceDirect), along with website and citation searching, to identify studies before March 15, 2025. Studies assessing the effect of H. pylori eradication on lipid profiles and CVD risk were included. Meta-analysis with subsequent subgroup, meta-regression, and sensitivity analysis was performed using RStudio.
Results: A total of 24 studies were included. Successful H. pylori eradication significantly improved LDL levels (MD: -2.46 mg/dL; -4.70 to -0.22; p = 0.03) and HDL levels (1.83 mg/dL; 0.51–3.16; p = 0.01). Meta-analyses of TC and TG changes yielded comparable results; however, meta-regression revealed that age was a significant covariate, revealing a trend toward significance in younger patients. Comparison analysis showed that significant results were only achieved in HDL changes between successful and unsuccessful eradication. Qualitatively, H. pylori eradication appeared to confer a beneficial effect on CVD risk, although this was likely indirect and influenced by patient-specific characteristics, including age and comorbidities.
Conclusion: H. pylori eradication was associated with modest improvements in lipid profiles, particularly HDL and LDL, and may contribute to reduced CVD risk, especially in younger individuals. Successful eradication may therefore be considered as one of the efforts to enhance lipid profiles and reduce CVD risk.
- Cardiovascular
- Eradication
- Helicobacter pylori
- Lipid
How to Cite
References
1. Chen YC, Malfertheiner P, Yu HT, Kuo CL, Chang YY, Meng FT, et al. Global prevalence of helicobacter pylori infection and incidence of gastric cancer between 1980 and 2022. Gastroenterology 2024;166:605–19.
2. Syam AF, Miftahussurur M, Makmun D, Nusi IA, Zain LH, Zulkhairi, et al. Risk factors and prevalence of helicobacter pylori in five largest islands of Indonesia: a preliminary study. PLoS One 2015;10:0140186.
3. Chey WD, Howden CW, Moss SF, Morgan DR, Greer KB, Grover S, et al. ACG clinical guideline: treatment of helicobacter pylori infection. Am J Gastroenterol 2024;119:1730-53.
4. Mahachai V, Vilaichone RK, Pittayanon R, Rojborwonwitaya J, Leelakusolvong S, Maneerattanaporn M, et al. Helicobacter pylori management in ASEAN: The Bangkok consensus report. J Gastroenterol Hepatol 2018;33:37–56.
5. Wang JW, Tseng KL, Hsu CN, Liang CM, Tai WC, Ku MK, et al. Association between Helicobacter pylori eradication and the risk of coronary heart diseases. PLoS One 2018;13:1–15.
6. Sun L, Zheng H, Qiu M, Hao S, Liu X, Zhu X, et al. Helicobacter pylori infection and risk of cardiovascular disease. Helicobacter 2023;28:12967.
7. Niccoli G, Franceschi F, Cosentino N, Giupponi B, De Marco G, Merra G, et al. Coronary atherosclerotic burden in patients with infection by CagA-positive strains of Helicobacter pylori. Coron Artery Dis 2010;21:217–21.
8. Jamkhande PG, Gattani SG, Farhat SA. Helicobacter pylori and cardiovascular complications: a mechanism based review on role of Helicobacter pylori in cardiovascular diseases. Integr Med Res 2016;5:244–9.
9. Li X, Li J. Predictive value of lipid levels in coronary heart disease in elderly hypertensive patients. Am J Transl Res 2025;17:2754–63.
10. Watanabe J, Hamasaki M, Kotani K. The effect of helicobacter pylori eradication on lipid levels: A meta-analysis. J Clin Med 2021;10:1–14.
11. Zuin M, Rigatelli G, Del Favero G, Picariello C, Meggiato T, Conte L, et al. Coronary artery disease and Helicobacter pylori infection: Should we consider eradication therapy as cardiovascular prevention strategy? Int J Cardiol 2016;223:711–2.
12. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. BMJ 2021;372.
13. Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol 2010;25:603–5.
14. Adachi K, Mishiro T, Okimoto E, Kinoshita Y. Influence of the degree of gastric mucosal atrophy on the serum lipid levels before and after the eradication of helicobacter pylori infection. Intern Med 2018;57:3067–73.
15. Ichikawa H, Sugimoto M, Sakao Y, Sahara S, Ohashi N, Sano K, et al. Eradication therapy for Helicobacter pylori infection improves nutrition status in Japanese hemodialysis patients: A pilot study. J Clin Biochem Nutr 2019;64:91–5.
16. Iwai N, Okuda T, Oka K, Hara T, Inada Y, Tsuji T, et al. Helicobacter pylori eradication increases the serum high density lipoprotein cholesterol level in the infected patients with chronic gastritis: A single-center observational study. PLoS One 2019;14:1–11.
17. Jalalzadeh M, Ghadiani MH, Mousavinasab N. Association between helicobacter pylori infection and body mass index, before and after eradication of infection in hemodialysis batients. J Nephropathol 2012;1:170–6.
18. Jamali A, Karbalai S, Tefagh G, Jamali R, Ahmadi A. The effects of helicobacter pylori eradication on liver function and metabolic profile in non-diabetic non-alcoholic steatohepatitis: a 5-year randomized clinical trial. Middle East J Dig Dis 2022;14:85–95.
19. Kamada T, Hata J, Kusunoki H, Ito M, Tanaka S, Kawamura Y, et al. Eradication of Helicobacter pylori increases the incidence of hyperlipidaemia and obesity in peptic ulcer patients. Dig Liver Dis 2005;37:39–43.
20. Kanbay M, Gür G, Yücel M, Yilmaz U, Boyacioĝlu S. Does eradication of Helicobacter pylori infection help normalize serum lipid and CRP levels? Dig Dis Sci 2005;50:1228–31.
21. Kim Y Il, Kim YA, Lee JW, Kim HJ, Kim SH, Kim SG, et al. Effect of Helicobacter pylori treatment on long-term mortality in patients with hypertension. Gut Liver 2020;14:47–56.
22. Kim JW, Baeg MK, Bang CS, Park JK, Oh JH. Effect of Helicobacter pylori eradication on body weight: a multicenter propensity score-matched analysis in Korea. J Neurogastroenterol Motil 2023;29:352–9.
23. Maruyama M, Kamimura K, Hoshiyama A, Hoshiyama K, Hoshiyama M, Hoshiyama Y, et al. Effect of Helicobacter pylori eradication on elder cases: Observational study in community-based medicine. World J Clin Cases 2017;5:412–8.
24. Nam SY, Ryu KH, Park BJ, Park S. Effects of helicobacter pylori infection and its eradication on lipid profiles and cardiovascular diseases. Helicobacter 2015;20:125–32.
25. Alavinejad P, Hajiani E, Parsi A, Satari A, Rezaei MJ, Nayebi M, et al. Effect of Helicobacter pylori eradication on metabolic profile: an international, multicenter, case-control study. BMC Gastroenterol 2022;22:1–9.
26. Park J, Kim N, Kim WS, Lim SH, Choi Y, Jo HH, et al. Long-term effects of the eradication of Helicobacter pylori on metabolic parameters, depending on sex, in South Korea. Gut Liver 2022;17:58–68.
27. Park Y, Kim TJ, Lee H, Yoo H, Sohn I, Min YW, et al. Eradication of Helicobacter pylori infection decreases risk for dyslipidemia: A cohort study. Helicobacter 2020;26:1–9.
28. Scharnagl H, Kist M, Grawitz AB, Koenig W, Wieland H, März W. Effect of Helicobacter pylori eradication on high-density lipoprotein cholesterol. Am J Cardiol 2004;93:219–20.
29. Wang Z, Wang W, Gong R, Yao H, Fan M, Zeng J, et al. Eradication of Helicobacter pylori alleviates lipid metabolism deterioration: a large-cohort propensity score-matched analysis. Lipids Health Dis 2022;21:1–10.
30. Bae SE, Choi KD, Choe J, Lee MJ, Kim S, Choi JY, et al. Effect of Helicobacter pylori eradication on metabolic parameters and body composition including skeletal muscle mass: a matched case-control study. Gut Liver 2025;19:346–54.
31. Azuma T, Suto H, Ito Y, Muramatsu A, Ohtani M, Dojo M, et al. Eradication of Helicobacter pylori infection induces an increase in body mass index. Aliment Pharmacol Ther 2002;16:S240–4.
32. Chen Y, Wang Y, Ni B, Ying G, Zhang J. Relationship between Helicobacter pylori and hypertriglyceridemia in the population. J Clin Lipidol 2025;19:461–7.
33. De Luis DA, Avello AG, Lasuncion MA, Aller R, De Argila CM, De Miquel DB, et al. Improvement in lipid and haemostasis patterns after Helicobacter pylori infection eradication in type 1 diabetic patients. Clin Nutr 1999;18:227–31.
34. Elizalde JI, Pérez-Pujol S, Heras M, Sionis A, Casanovas N, Martorell T, et al. Effects of Helicobacter pylori eradication on platelet activation and disease recurrence in patients with acute coronary syndromes. Helicobacter 2004;9:681–9.
35. Elizalde JI, Piqué JM, Moreno V, Morillas JD, Elizalde I, Bujanda L, et al. Influence of Helicobacter pylori infection and eradication on blood lipids and fibrinogen. Aliment Pharmacol Ther 2002;16:577–86.
36. Gen R, Demir M, Ataseven H. Effect of helicobacter pylori eradication on insulin resistance, serum lipids and low-grade inflammation. South Med J 2010;103:190–6.
37. Manolakis A, Kapsoritakis AN, Potamianos SP. A review of the postulated mechanisms concerning the association of Helicobacter pylori with ischemic heart disease. Helicobacter 2007;12:287–97.
38. Saviano A, Morabito Loprete MR, Pignataro G, Piccioni A, Gasbarrini A, Franceschi F, et al. Helicobacter pylori, atherosclerosis, and coronary artery disease: a narrative review. Medicina 2025;61.
39. Nigatie M, Melak T, Asmelash D, Worede A. Dyslipidemia and its associated factors among helicobacter pylori-infected patients attending at university of gondar comprehensive specialized hospital, Gondar, north-west Ethiopia: a comparative cross-sectional study. J Multidiscip Healthc 2022;15:1481–91.
40. Sung KC, Rhee EJ, Ryu SH, Beck SH. Prevalence of Helicobacter pylori infection and its association with cardiovascular risk factors in Korean adults. Int J Cardiol 2005;102:411–7.
41. Song S, Shim JE. Trends in Dietary Intake of Total Fat and Fatty Acids Among Korean Adolescents from 2007 to 2017. Nutrients 2019;11:3073.
42. Franceschi F, Niccoli G, Ferrante G, Gasbarrini A, Baldi A, Candelli M, et al. CagA antigen of Helicobacter pylori and coronary instability: insight from a clinico-pathological study and a meta-analysis of 4241 cases. Atherosclerosis 2009;202:535–42.
43. Gwack J, Shin A, Kim CS, Ko KP, Kim Y, Jun JK, et al. CagA-producing Helicobacter pylori and increased risk of gastric cancer: A nested case-control study in Korea. Br J Cancer 2006;95:639–41.
44. Park Y, Ki M. Population attributable fraction of helicobacter pylori infection–related gastric cancer in Korea: a meta-analysis. Cancer Res Treat 2021;53:744–53.
45. Zuo Y, Chen S, Tian X, Wang P, Wu S, Wang A. Association of vascular aging with cardiovascular disease in middle-aged Chinese people: a prospective cohort study. JACC Asia 2023;3:895–904.
46. Cheng DCY, Climie RE, Shu M, Grieve SM, Kozor R, Figtree GA. Vascular aging and cardiovascular disease: pathophysiology and measurement in the coronary arteries. Front Cardiovasc Med 2023;10:1206156.
47. Epplein M, Signorello LB, Zheng W, Peek RM, Michel A, Williams SM, et al. Race, African ancestry, and Helicobacter pylori infection in a low-income United States population. Cancer Epidemiol Biomarkers Prev 2011;20:826–34.
- Abstract Viewed: 457 times
- PDF Downloaded: 273 times
- Supplementary Downloaded: 88 times